Shots:

• The P-III (ELEVATE 12) trial evaluates etrasimod (2mg, qd) vs PBO in 354 patients with UC who had prior failed or were intolerant to one conventional, biologic, or JAK therapy. The therapy has been developed by Arena & recently acquired by Pfizer
• The trial met its 1EPs & 2EPs i.e., patients achieved a significant improvement of clinical remission @12wks. The safety profile was consistent with previous P-II studies & the results will be submitted for future scientific publication & presentation
• The company will use these results along with the P-III (ELEVATE 52) study for future regulatory filings while the results from the (ELEVATE 52) study are expected to be available at end of Q1’22

Ref: Buisness Wire | Image: Pfizer